4b - Riassunto in atti di congresso

4b - Riassunto in atti di congresso: [10904] Home page tipologia

Sfoglia

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1.401 a 1.420 di 10.904

In vitro cell growth inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on human tumor cell lines with defective DNA damage response pathways

2015 Mini E, Landini I, Lucarini L, Nobili S, Masini E, Moroni F

ATP chemosensitivity testing: methodology and comparison with other methods

1994 Pinzani P, Gerli A, Carotti S, Mini E, Orlando C, Gelmini S, Sestini R, Pazzagli M

Correlation of methotrexate polyglutamate MTX(Glu) formation and cell kill in the human lymphoblast cell line CCRF-CEM

1983 Mini E, McGuire JJ, Moroson BA, Bertino JR

Cytotoxic effects of hyperthermia and 5-fluorouracil (FUra) on human leukemic CCRF-CEM cells

1984 Mini E, Dombrowski J, Moroson BA, Bertino JR

Leucovorin (LV)-fluoropyrimidine synergy in the human leukemic lymphoblast cell line CCRF-CEM

1985 Mini E, Moroson BA, Bertino JR

Differential efficacy of trimetrexate (2-diamino-6-methyl-(3,4,5-trimethoxyanilino)methyl)quinazoline, JB-11, TMQ) and methotrexate (MTX) on human colon carcinoma and human leukemia cells in vitro

1985 Mini E, Sobrero A, Moroson BA, Bertino JR

Effects of trimetrexate on human leukemia cells from patients sensitive and resistant to methotrexate (MTX)

1985 Bertino JR, Mini E, Sawicki WL, Moroson BA, Jastreboff M, McGuire JJ

Biochemical basis for cisplatinum and 5-fluorouracil synergism in human tumors

1986 Scanlon KJ, Nee Deels C, Lu Y, Lin C, Newman E, Leong L, Mini E

Impaired polyglutamylation as a mechanism of resistance to methotrexate (MTX) in human leukemia CCRF-CEM cells to high-dose short-term exposure to this drug

1987 Mini E, Pizzorno G, Mazzei T, Moroson BA, Cashmore AR, Bertino JR

Development of a RPWAX×RPLC-HRMS platform for the nontargeted identification of pfass in aqueous film-forming foams

2022 Lapo Renai, Andrea F. G. Gargano, Saer Samanipour, Peter J. Schoenmakers, Massimo Del Bubba

Sequence-dependent synergism between trimetrexate and 5-fluorouracil in a human colon carcinoma cell line

1987 Romanini A, Russello O, Rosso R, Nicolin A, Mini E, Moroson BA, Bertino JR, Sobrero A

Quality by Design optimization of a LC-MS/MS method for the analysis of heterogeneous pharmaceutical compounds and their screening in water samples

2022 Lapo Renai, Cristina Vanessa Agata Scordo, Ayoub El Ghadraoui, Sergio Santana-Viera, JoséJuan Santana Rodriguez, Serena Orlandini, Sandra Furlanetto, Donatella Fibbi, Dimitra Lambropoulou, Massimo Del Bubba

Phase I study of LY186641 given on alternative weeks to patients (pts) with solid tumors

1991 Mini E, Mazzei T, Ribecco A, Periti P

OPTIMIZING LVDI-LC-HRMS SENSITIVITY FOR NON-TARGETED ENVIRONMENTAL ANALYSIS BY DESIGN OF EXPERIMENTS

2022 Lapo Renai, Michelangelo Fichera, Andrea Ravalli, Matteo Sottile, Daniela Santianni, Massimo Del Bubba

Phase II study of 5-FU plus 6-S-leucovorin (6S-LV) in advanced colorectal cancer

1992 Sobrero A, Rosso R, Bolli E, Tixi L, Falcone A, Conte PF, Pancera G, La Bianca R, Di Costanzo F, Pronzato P, Mini E, Periti P

Adjuvant therapy of colorectal carcinoma with 5-fluorouracil (5-FU) and l-folinic acid (l-LV) alone or combined with levamisole (LEV) or interferon alpha2a (IFN alpha2a). Preliminary toxicological results of a multicenter study of the Gruppo Oncologico-Chirurgico Cooperativo Italiano (GOCCI)

1995 Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Mazzoni P

A randomized multicenter study comparing 5-fluorouracil (5-FU) and l-folinic acid (L-LV) alone or with levamisole (LEV) or interferon alpha2a (IFNalpha2a) as adjuvant therapy for colorectal cancer

1996 Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Mazzoni P

Improving the annotation of post-prandial metabolites in human urine samples from an untargeted LC-MS-based bilberry-blueberry intervention study by Feature-Based Molecular Networking

2021 Lapo Renai, Marynka Ulaszewska, Massimo Del Bubba, Justin J.J. van der Hooft

Molecular analysis of the FHIT gene in human sporadic colon cancers.

1999 Luceri C, De Filippo C, Caderni G, Mini E, Napoli C, Tonelli F, Cortesini C, Dolara P

Untargeted metabolomics reveals different postprandial serum metabolome profiles after single intake of Vaccinium myrtillus and Vaccinium corymbosum.

2021 Lapo Renai, Marynka Ulaszewska, Claudia Ancillotti, Mar Garcia-Aloy, Fulvio Mattivi, Massimo Del Bubba

Titolo	Data di pubblicazione	Autore(i)
In vitro cell growth inhibitory effects of HYDAMTIQ, a novel PARP inhibitor, on human tumor cell lines with defective DNA damage response pathways	2015	Mini E, Landini I, Lucarini L, Nobili S, Masini E, Moroni F
ATP chemosensitivity testing: methodology and comparison with other methods	1994	Pinzani P, Gerli A, Carotti S, Mini E, Orlando C, Gelmini S, Sestini R, Pazzagli M
Correlation of methotrexate polyglutamate MTX(Glu) formation and cell kill in the human lymphoblast cell line CCRF-CEM	1983	Mini E, McGuire JJ, Moroson BA, Bertino JR
Cytotoxic effects of hyperthermia and 5-fluorouracil (FUra) on human leukemic CCRF-CEM cells	1984	Mini E, Dombrowski J, Moroson BA, Bertino JR
Leucovorin (LV)-fluoropyrimidine synergy in the human leukemic lymphoblast cell line CCRF-CEM	1985	Mini E, Moroson BA, Bertino JR
Differential efficacy of trimetrexate (2-diamino-6-methyl-(3,4,5-trimethoxyanilino)methyl)quinazoline, JB-11, TMQ) and methotrexate (MTX) on human colon carcinoma and human leukemia cells in vitro	1985	Mini E, Sobrero A, Moroson BA, Bertino JR
Effects of trimetrexate on human leukemia cells from patients sensitive and resistant to methotrexate (MTX)	1985	Bertino JR, Mini E, Sawicki WL, Moroson BA, Jastreboff M, McGuire JJ
Biochemical basis for cisplatinum and 5-fluorouracil synergism in human tumors	1986	Scanlon KJ, Nee Deels C, Lu Y, Lin C, Newman E, Leong L, Mini E
Impaired polyglutamylation as a mechanism of resistance to methotrexate (MTX) in human leukemia CCRF-CEM cells to high-dose short-term exposure to this drug	1987	Mini E, Pizzorno G, Mazzei T, Moroson BA, Cashmore AR, Bertino JR
Development of a RPWAX×RPLC-HRMS platform for the nontargeted identification of pfass in aqueous film-forming foams	2022	Lapo Renai, Andrea F. G. Gargano, Saer Samanipour, Peter J. Schoenmakers, Massimo Del Bubba
Sequence-dependent synergism between trimetrexate and 5-fluorouracil in a human colon carcinoma cell line	1987	Romanini A, Russello O, Rosso R, Nicolin A, Mini E, Moroson BA, Bertino JR, Sobrero A
Quality by Design optimization of a LC-MS/MS method for the analysis of heterogeneous pharmaceutical compounds and their screening in water samples	2022	Lapo Renai, Cristina Vanessa Agata Scordo, Ayoub El Ghadraoui, Sergio Santana-Viera, JoséJuan Santana Rodriguez, Serena Orlandini, Sandra Furlanetto, Donatella Fibbi, Dimitra Lambropoulou, Massimo Del Bubba
Phase I study of LY186641 given on alternative weeks to patients (pts) with solid tumors	1991	Mini E, Mazzei T, Ribecco A, Periti P
OPTIMIZING LVDI-LC-HRMS SENSITIVITY FOR NON-TARGETED ENVIRONMENTAL ANALYSIS BY DESIGN OF EXPERIMENTS	2022	Lapo Renai, Michelangelo Fichera, Andrea Ravalli, Matteo Sottile, Daniela Santianni, Massimo Del Bubba
Phase II study of 5-FU plus 6-S-leucovorin (6S-LV) in advanced colorectal cancer	1992	Sobrero A, Rosso R, Bolli E, Tixi L, Falcone A, Conte PF, Pancera G, La Bianca R, Di Costanzo F, Pronzato P, Mini E, Periti P
Adjuvant therapy of colorectal carcinoma with 5-fluorouracil (5-FU) and l-folinic acid (l-LV) alone or combined with levamisole (LEV) or interferon alpha2a (IFN alpha2a). Preliminary toxicological results of a multicenter study of the Gruppo Oncologico-Chirurgico Cooperativo Italiano (GOCCI)	1995	Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Mazzoni P
A randomized multicenter study comparing 5-fluorouracil (5-FU) and l-folinic acid (L-LV) alone or with levamisole (LEV) or interferon alpha2a (IFNalpha2a) as adjuvant therapy for colorectal cancer	1996	Tonelli F, Periti P, Mazzei T, Mini E, Ficari F, Valanzano R, Mazzoni P
Improving the annotation of post-prandial metabolites in human urine samples from an untargeted LC-MS-based bilberry-blueberry intervention study by Feature-Based Molecular Networking	2021	Lapo Renai, Marynka Ulaszewska, Massimo Del Bubba, Justin J.J. van der Hooft
Molecular analysis of the FHIT gene in human sporadic colon cancers.	1999	Luceri C, De Filippo C, Caderni G, Mini E, Napoli C, Tonelli F, Cortesini C, Dolara P
Untargeted metabolomics reveals different postprandial serum metabolome profiles after single intake of Vaccinium myrtillus and Vaccinium corymbosum.	2021	Lapo Renai, Marynka Ulaszewska, Claudia Ancillotti, Mar Garcia-Aloy, Fulvio Mattivi, Massimo Del Bubba

Prodotti della tipologia (ordinati per Data di deposito in Decrescente ordine): 1.401 a 1.420 di 10.904

Legenda icone

file ad accesso aperto
file disponibili sulla rete interna
file disponibili agli utenti autorizzati
file disponibili solo agli amministratori
file sotto embargo
nessun file disponibile

Scopri

Accesso al fulltext

no fulltext8389
open1402
reserved1104
partially open6
embargoed3